	US 12,419,954 B2
	Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies
Christine E. Brown, Duarte, CA (US); Lawrence Stern, Duarte, CA (US); Xin Yang, Duarte, CA (US); K. Christopher Garcia, Duarte, CA (US); and Ignacio Moraga Gonzalez, Duarte, CA (US)
Assigned to City of Hope, Duarte, CA (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/796,349
Filed by City of Hope, Duarte, CA (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Jan. 19, 2021, PCT No. PCT/US2021/014008 § 371(c)(1), (2) Date Jul. 29, 2022, PCT Pub. No. WO2021/154543, PCT Pub. Date Aug. 5, 2021.
Claims priority of provisional application 62/968,975, filed on Jan. 31, 2020.
Prior Publication US 2023/0372483 A1, Nov. 23, 2023
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01)

CPC A61K 40/31 (2025.01) [A61K 40/11 (2025.01); A61K 40/4217 (2025.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05)]

20 Claims

1. A nucleic molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein—the CAR comprises or consists of an amino acid sequence selected from the group consisting of an amino acid sequence that is at least 98% identical to an amino acid sequence selected from SEQ ID NOs: 29, 30, 32, 33, 35, 36, 38 and 39 and comprises a targeting domain comprising or consisting of an amino acid sequence identical to SEQ ID NO: 26 or 27.